IL140117A0 - Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders - Google Patents

Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders

Info

Publication number
IL140117A0
IL140117A0 IL14011799A IL14011799A IL140117A0 IL 140117 A0 IL140117 A0 IL 140117A0 IL 14011799 A IL14011799 A IL 14011799A IL 14011799 A IL14011799 A IL 14011799A IL 140117 A0 IL140117 A0 IL 140117A0
Authority
IL
Israel
Prior art keywords
norcisapride
bulimia
apnea
disorders
treatment
Prior art date
Application number
IL14011799A
Other languages
English (en)
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of IL140117A0 publication Critical patent/IL140117A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
IL14011799A 1998-06-15 1999-06-10 Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders IL140117A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8922598P 1998-06-15 1998-06-15
US12223699P 1999-03-01 1999-03-01
PCT/US1999/013100 WO1999065490A2 (fr) 1998-06-15 1999-06-10 Procedes permettant de traiter l'apnee, la boulimie et d'autres troubles au moyen du norcisapride (-) optiquement pur

Publications (1)

Publication Number Publication Date
IL140117A0 true IL140117A0 (en) 2002-02-10

Family

ID=26780367

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14011799A IL140117A0 (en) 1998-06-15 1999-06-10 Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders

Country Status (24)

Country Link
US (2) US6559165B1 (fr)
EP (1) EP1087765B1 (fr)
JP (1) JP2003522103A (fr)
KR (3) KR20060067985A (fr)
CN (1) CN1312716A (fr)
AR (1) AR020327A1 (fr)
AT (1) ATE291916T1 (fr)
AU (1) AU764474B2 (fr)
BG (1) BG105097A (fr)
BR (1) BR9911302A (fr)
CA (1) CA2334369A1 (fr)
CZ (1) CZ20004736A3 (fr)
DE (1) DE69924488T2 (fr)
ES (1) ES2237117T3 (fr)
HK (1) HK1040059A1 (fr)
HU (1) HUP0102026A3 (fr)
IL (1) IL140117A0 (fr)
IS (1) IS5755A (fr)
NO (1) NO20006358L (fr)
NZ (3) NZ526108A (fr)
PL (1) PL345325A1 (fr)
SK (1) SK19062000A3 (fr)
TR (6) TR200103758T2 (fr)
WO (1) WO1999065490A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6663639B1 (en) 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US8287554B2 (en) 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US8512751B2 (en) 2004-12-20 2013-08-20 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (fr) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide; derives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4598123A (en) 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
US5116407A (en) 1988-10-13 1992-05-26 Courtaulds Coatings Limited Antifouling coatings
JPH02188523A (ja) 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
ATE170747T1 (de) * 1991-12-21 1998-09-15 Smithkline Beecham Plc Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2139636A1 (fr) 1992-07-07 1994-01-20 Nancy M. Gray Methodes d'utilisation de la (+) cisapride pour le traitement du reflux gastro-oesophagien et d'autres troubles
EP1145715A3 (fr) 1992-07-07 2004-05-19 Sepracor Inc. Procédés d'utilisation de cisapride pour le traitement du reflux gastro-sophagien et d'autres troubles
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
WO1995001803A1 (fr) 1993-07-06 1995-01-19 Merck & Co., Inc. Combinaisons d'agents anti-h2 et d'agents de motilite gastro-intestinale
US5407953A (en) 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
US5502067A (en) 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5712293A (en) 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
JP3529102B2 (ja) * 1997-07-11 2004-05-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ ５−ｈｔ３および５−ｈｔ４介在性障害に有用な（＋）−ノルシサプリド
EP1089733B1 (fr) 1998-06-15 2005-03-23 Sepracor Inc. Utilisation du (+) norcisapride optiquement pur pour traiter le syndrome du colon irritable

Also Published As

Publication number Publication date
TR200003707T2 (tr) 2001-06-21
PL345325A1 (en) 2001-12-17
NO20006358L (no) 2001-02-13
TR200103758T2 (tr) 2002-06-21
TR200103759T2 (tr) 2002-06-21
HUP0102026A2 (hu) 2001-11-28
TR200103760T2 (tr) 2002-06-21
NO20006358D0 (no) 2000-12-13
NZ508825A (en) 2003-09-26
ATE291916T1 (de) 2005-04-15
NZ535055A (en) 2006-04-28
SK19062000A3 (sk) 2001-07-10
DE69924488T2 (de) 2005-09-08
US20030158229A1 (en) 2003-08-21
WO1999065490A3 (fr) 2000-04-13
CZ20004736A3 (cs) 2001-09-12
BR9911302A (pt) 2001-03-13
US6559165B1 (en) 2003-05-06
DE69924488D1 (de) 2005-05-04
KR20010052740A (ko) 2001-06-25
WO1999065490A2 (fr) 1999-12-23
EP1087765A2 (fr) 2001-04-04
CN1312716A (zh) 2001-09-12
AR020327A1 (es) 2002-05-08
TR200103762T2 (tr) 2002-05-21
TR200103757T2 (tr) 2002-06-21
HK1040059A1 (zh) 2002-05-24
NZ526108A (en) 2004-10-29
HUP0102026A3 (en) 2002-12-28
AU764474B2 (en) 2003-08-21
CA2334369A1 (fr) 1999-12-23
KR20060020739A (ko) 2006-03-06
US7064138B2 (en) 2006-06-20
EP1087765B1 (fr) 2005-03-30
BG105097A (en) 2002-02-28
JP2003522103A (ja) 2003-07-22
AU4678499A (en) 2000-01-05
ES2237117T3 (es) 2005-07-16
IS5755A (is) 2000-12-08
KR20060067985A (ko) 2006-06-20

Similar Documents

Publication Publication Date Title
PL345275A1 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
IL138732A0 (en) The use of polyamines in the treatment of dermatological symptoms
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
GB9914080D0 (en) Humidified sleep apnea treatment apparatus
AU2003291609A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
HK1070361A1 (en) 5-sulphanyl-4h-1,2,4-triazole derivatives and their use to treat disorders associated with somatostatine
AU4678897A (en) Humidifier sleep apnea treatment apparatus
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
NO20001754D0 (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
EP0924983A4 (fr) S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
AU5845099A (en) Use of (pex) in the treatment of metabolic bone diseases
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
AU2003286285A1 (en) Use of fgf-18 in the diagnosis and treatment of memory disorders
PL345325A1 (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
HUP0000873A3 (en) The use of levobupivacaine in facial surgery
GB0128674D0 (en) Treatment of sleep disorders and the like
AU5262200A (en) Arrangement in ventilatory treatment of the lungs
PL351554A1 (en) Osanetant in the treatment of mood disorders
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
ZA200007259B (en) Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders.
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
IS5324A (is) (S) 2-Metýlamínó-2-fenýl-n-bútýl 3,4,5-trímetoxý-bensóat, notkun þess til meðferðar á langvinnum sársauka
AU3061199A (en) Skin treatment compositions and the use thereof